{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:53:28Z","timestamp":1760298808958},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1097\/cnq.0b013e3182a10d2f","type":"journal-article","created":{"date-parts":[[2013,10,11]],"date-time":"2013-10-11T22:38:15Z","timestamp":1381531095000},"page":"345-355","source":"Crossref","is-referenced-by-count":7,"title":["Trends in Multidrug-Resistant Gram-Negative Bacilli and the Role of Prolonged \u03b2-Lactam Infusion in the Intensive Care Unit"],"prefix":"10.1097","volume":"36","author":[{"given":"David J.","family":"Guervil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terence","family":"Chau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"3","key":"R1-4-20210126","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"R2-4-20210126","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/archinte.162.2.185","article-title":"Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species.","volume":"162","author":"Cosgrove","year":"2002","journal-title":"Arch Intern Med"},{"key":"R3-4-20210126","doi-asserted-by":"crossref","first-page":"298","DOI":"10.7326\/0003-4819-134-4-200102200-00014","article-title":"Antibiotic resistance in the intensive care unit setting.","volume":"134","author":"Kollef","year":"2001","journal-title":"Ann Intern Med"},{"key":"R4-4-20210126","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1086\/432803","article-title":"Overview of nosocomial infections caused by gram-negative bacilli.","volume":"41","author":"Gaynes","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"1","key":"R5-4-20210126","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10096-007-0389-y","article-title":"New antimicrobial agents as therapy for resistant gram-positive cocci.","volume":"27","author":"Lentino","year":"2008","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"suppl 2","key":"R6-4-20210126","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/j.ijantimicag.2010.11.014","article-title":"Multidrug-resistant gram-negative bacteria: how to treat and for how long.","volume":"36","author":"Giamarellou","year":"2010","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"R7-4-20210126","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1086\/510590","article-title":"Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.","volume":"44","author":"Lodise","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"2","key":"R8-4-20210126","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1592\/phco.28.2.235","article-title":"The current state of multidrug-resistant gram-negative bacilli in North America.","volume":"28","author":"Nicasio","year":"2008","journal-title":"Pharmacotherapy"},{"issue":"4","key":"R10-4-20210126","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/CMR.18.4.657-686.2005","article-title":"Extended-spectrum beta-lactamases: a clinical update.","volume":"18","author":"Paterson","year":"2005","journal-title":"Clin Microbiol Rev"},{"issue":"4","key":"R11-4-20210126","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.diagmicrobio.2005.04.004","article-title":"Regional variation in the prevalence of extended-spectrum beta-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998-2002).","volume":"52","author":"Hirakata","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"4","key":"R12-4-20210126","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0732-8893(98)00124-2","article-title":"Antimicrobial susceptibility patterns for pathogens isolated from patients in Latin American medical centers with a diagnosis of pneumonia: analysis of results from the SENTRY Antimicrobial Surveillance Program (1997). SENTRY Latin America Study Group.","volume":"32","author":"Sader","year":"1998","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R13-4-20210126","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.diagmicrobio.2005.06.004","article-title":"In vitro activity of tigecycline against 3989 gram-negative and gram-positive clinical isolates from the United States tigecycline evaluation and surveillance trial (TEST program, 2004).","volume":"52","author":"Bouchillon","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"R14-4-20210126","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1128\/CMR.00036-08","article-title":"AmpC beta-lactamases.","volume":"22","author":"Jacoby","year":"2009","journal-title":"Clin Microbiol Rev"},{"issue":"5","key":"R15-4-20210126","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/j.1875-9114.2012.01035.x","article-title":"Klebsiella pneumoniae carbapenemases in Enterobacteriaceae: history, evolution, and microbiology concerns.","volume":"32","author":"Rapp","year":"2012","journal-title":"Pharmacotherapy"},{"issue":"4","key":"R16-4-20210126","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.diagmicrobio.2009.08.020","article-title":"Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008).","volume":"65","author":"Rhomberg","year":"2009","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"R17-4-20210126","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1586\/eri.09.108","article-title":"Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy.","volume":"8","author":"Zavascki","year":"2010","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"2","key":"R18-4-20210126","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/cid\/cir790","article-title":"-Lactam-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum -lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts.","volume":"54","author":"Rodriguez-Bano","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"1","key":"R19-4-20210126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokineticpharmacodynamic parameters: rationale for antibacterial dosing of mice and men.","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"issue":"1","key":"R20-4-20210126","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccc.2010.11.004","article-title":"Pharmacodynamic approaches to optimizing beta-lactam therapy.","volume":"27","author":"Crandon","year":"2011","journal-title":"Crit Care Clin"},{"issue":"suppl 1","key":"R21-4-20210126","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1086\/344653","article-title":"Prevention of resistance: a goal for dose selection for antimicrobial agents.","volume":"36","author":"Drusano","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R23-4-20210126","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/IPC.0b013e31822e9bf5","article-title":"Retrospective study of prolonged versus intermittment infusion piperacillin-tazobactam and meropenem in intensive care unit patients at an academic medical center.","volume":"19","author":"Dow","year":"2011","journal-title":"Infect Dis Clin Pract"},{"issue":"2","key":"R24-4-20210126","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/cid\/cis856","article-title":"Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial.","volume":"56","author":"Dulhunty","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"5","key":"R25-4-20210126","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ijantimicag.2008.10.025","article-title":"Clinical cure of ventilator-associated pneumonia treated with piperacillintazobactam administered by continuous or intermittent infusion.","volume":"33","author":"Lorente","year":"2009","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"R26-4-20210126","doi-asserted-by":"crossref","first-page":"e49845","DOI":"10.1371\/journal.pone.0049845","article-title":"Continuous infusion of piperacillintazobactam in septic critically ill patientsa multicenter propensity matched analysis.","volume":"7","author":"Goncalves-Pereira","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"R27-4-20210126","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijantimicag.2006.02.020","article-title":"Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients.","volume":"28","author":"Rafati","year":"2006","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"R28-4-20210126","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0002-9610(00)00388-3","article-title":"Intermittent and continuous ceftazidime infusion for critically ill trauma patients.","volume":"179","author":"Hanes","year":"2000","journal-title":"Am J Surg"},{"issue":"6","key":"R29-4-20210126","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0924-8579(01)00329-6","article-title":"Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia.","volume":"17","author":"Nicolau","year":"2001","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"R30-4-20210126","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.clinthera.2007.11.003","article-title":"Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review.","volume":"29","author":"Lorente","year":"2007","journal-title":"Clin Ther"},{"issue":"8","key":"R31-4-20210126","doi-asserted-by":"crossref","first-page":"360","DOI":"10.5414\/CPP43360","article-title":"Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen.","volume":"43","author":"Georges","year":"2005","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"2","key":"R32-4-20210126","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1345\/aph.1G467","article-title":"Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli.","volume":"40","author":"Lorente","year":"2006","journal-title":"Ann Pharmacother"},{"issue":"3","key":"R33-4-20210126","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ijantimicag.2008.09.012","article-title":"Experience with extended-infusion merop-enem in the management of ventilator-associated pneumonia due to multidrug-resistant Acinetobacter baumannii.","volume":"33","author":"Wang","year":"2009","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"R34-4-20210126","doi-asserted-by":"crossref","first-page":"R113","DOI":"10.1186\/cc11405","article-title":"Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial.","volume":"16","author":"Chytra","year":"2012","journal-title":"Crit Care"},{"issue":"2","key":"R35-4-20210126","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/cid\/cis857","article-title":"Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillintazobactam: a systematic review and meta-analysis.","volume":"56","author":"Falagas","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"2","key":"R36-4-20210126","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/jac\/dkl478","article-title":"Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care A randomized controlled pilot study.","volume":"59","author":"Roberts","year":"2007","journal-title":"J Antimicrob Chemother"}],"container-title":["Critical Care Nursing Quarterly"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CNQ.0b013e3182a10d2f","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:57:33Z","timestamp":1620950253000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002727-201310000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/cnq.0b013e3182a10d2f","relation":{},"ISSN":["0887-9303"],"issn-type":[{"value":"0887-9303","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}